{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:49:47Z","timestamp":1792082987703,"version":"4.4.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Epcoritamab is a subcutaneous CD3\u00d7CD20 bispecific antibody approved as monotherapy for relapsed\/refractory (R\/R) follicular lymphoma (FL). We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R\/R FL in arm 2 of EPCORE NHL-2 (phase 1b\/2). Patients received epcoritamab (2 step-up doses, then 48-mg full doses) for up to 2 years, and R2 for up to 12 cycles (28 days per cycle). The primary end point was overall response rate (ORR) per investigator assessment (Lugano criteria). As of 21 September 2024, 108 patients received \u22651 epcoritamab dose in expansion (median follow-up, 28.2 months). Median age was 65 years; 57% had 1 previous line of therapy. ORR and complete response (CR) rate were 96% and 88%, respectively; CR rates in patients with high-risk features were 90% (primary refractory), 82% (refractory to anti-CD20 and an alkylating agent), and 83% (disease progression within 24 months of first-line therapy). Two-year estimates for remaining in CR, progression-free survival, overall survival, and not starting next antilymphoma therapy were 82%, 76%, 90%, and 84%, respectively. Minimal residual disease negativity was observed in 86% of evaluable patients (clonoSEQ assay). Common treatment-emergent adverse events (TEAEs) included neutropenia (65%), COVID-19 (59%), and cytokine release syndrome (CRS; 51%). Grade \u22653 TEAEs occurred in 87% of patients; 5 had grade 5 TEAEs (all COVID-19). CRS events were mostly low grade (grade 1, 38%; grade 2, 11%; grade 3, 2%), all resolved, and none led to epcoritamab discontinuation. Fixed-duration epcoritamab plus R2 demonstrated deep, durable responses with manageable safety and favorable outcomes in R\/R FL, irrespective of risk features. This trial was registered at www.ClinicalTrials.gov as #NCT04663347.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025029909","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T17:16:57Z","timestamp":1757351817000},"page":"2629-2640","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1531-3838","authenticated-orcid":false,"given":"Lorenzo","family":"Falchi","sequence":"first","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"2Clinical Hematology Department, Institut Catal\u00e0 d\u2019Oncologia, L\u2019Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-511X","authenticated-orcid":false,"given":"Sirpa","family":"Lepp\u00e4","sequence":"additional","affiliation":[{"name":"3Department of Oncology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1628-6256","authenticated-orcid":false,"given":"Joost S. P.","family":"Vermaat","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-2873","authenticated-orcid":false,"given":"Marcel","family":"Nijland","sequence":"additional","affiliation":[{"name":"5Department of Hematology, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Haaber","family":"Christensen","sequence":"additional","affiliation":[{"name":"6Department of Haematology, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"de Vos","sequence":"additional","affiliation":[{"name":"7Department of Medicine, Hematology\/Oncology, Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9799-9428","authenticated-orcid":false,"given":"Harald","family":"Holte","sequence":"additional","affiliation":[{"name":"8Department of Oncology, Oslo University Hospital and KG Jebsen Center for B-cell Malignancies, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid W.","family":"Merryman","sequence":"additional","affiliation":[{"name":"9Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6735-8651","authenticated-orcid":false,"given":"Pieternella J.","family":"Lugtenburg","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9625-7422","authenticated-orcid":false,"given":"Pau","family":"Abrisqueta","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Hospital Universitario Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3294-1548","authenticated-orcid":false,"given":"Kim M.","family":"Linton","sequence":"additional","affiliation":[{"name":"12Division of Cancer Sciences, The Christie NHS Foundation Trust, Manchester Cancer Research Centre, University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Sunkersett","sequence":"additional","affiliation":[{"name":"13AbbVie, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Hoehn","sequence":"additional","affiliation":[{"name":"14Genmab, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Rana","sequence":"additional","affiliation":[{"name":"14Genmab, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqeel","family":"Abbas","sequence":"additional","affiliation":[{"name":"14Genmab, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Marek","sequence":"additional","affiliation":[{"name":"14Genmab, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hao","sequence":"additional","affiliation":[{"name":"14Genmab, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Steele","sequence":"additional","affiliation":[{"name":"14Genmab, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Morehouse","sequence":"additional","affiliation":[{"name":"14Genmab, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-1741","authenticated-orcid":false,"given":"Martin","family":"Hutchings","sequence":"additional","affiliation":[{"name":"15Department of Haematology, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Belada","sequence":"additional","affiliation":[{"name":"164th Department of Internal Medicine, Haematology, Hospital and Faculty of Medicine, Charles University, Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2025112711214503600_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025112711214503600_bib2","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3324\/haematol.2022.281421","article-title":"Treatment patterns and outcomes in relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study","volume":"108","author":"Ghione","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"2025112711214503600_bib3","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.15149","article-title":"Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study","volume":"184","author":"Link","year":"2019","journal-title":"Br J Haematol"},{"issue":"24","key":"2025112711214503600_bib4","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1182\/blood.2019001751","article-title":"Lenalidomide in follicular lymphoma","volume":"135","author":"Flowers","year":"2020","journal-title":"Blood"},{"key":"2025112711214503600_bib5","doi-asserted-by":"crossref","first-page":"1120358","DOI":"10.3389\/fonc.2023.1120358","article-title":"Treatment selection for patients with relapsed or refractory follicular lymphoma","volume":"13","author":"Skarbnik","year":"2023","journal-title":"Front Oncol"},{"issue":"21","key":"2025112711214503600_bib6","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2025112711214503600_bib7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.15797","article-title":"Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma","volume":"185","author":"Chiu","year":"2019","journal-title":"Br J Haematol"},{"issue":"14","key":"2025112711214503600_bib8","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"23","key":"2025112711214503600_bib9","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2025112711214503600_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.7502","article-title":"Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed\/refractory NHL: analysis of patients with double-refractory or early relapsed follicular lymphoma (FL) [abstract]","volume":"35","author":"Andorsky","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025112711214503600_bib11","author":"Epkinly. Package insert","year":"2024"},{"key":"2025112711214503600_bib12","author":"Tepkinly. Summary of product characteristics","year":"2024"},{"key":"2025112711214503600_bib13","author":"Epkinly. Japan package insert","year":"2025"},{"issue":"8","key":"2025112711214503600_bib14","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2025112711214503600_bib15","doi-asserted-by":"crossref","first-page":"9283","DOI":"10.1182\/blood-2022-162538","article-title":"Evaluation of epcoritamab and rituximab combination in preclinical models of B-cell non-Hodgkin's lymphoma (NHL) [abstract]","volume":"140","author":"Epling-Burnette","year":"2022","journal-title":"Blood"},{"issue":"20","key":"2025112711214503600_bib16","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"suppl 5","key":"2025112711214503600_bib17","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol"},{"issue":"27","key":"2025112711214503600_bib18","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025112711214503600_bib19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"16","key":"2025112711214503600_bib20","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025112711214503600_bib21","unstructured":"ICH Expert Working Group\n          . ICH Harmonised Tripartite Guideline Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A. 1994. Accessed 21 July 2025. https:\/\/database.ich.org\/sites\/default\/files\/E2A_Guideline.pdf."},{"issue":"9","key":"2025112711214503600_bib22","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.clml.2024.04.009","article-title":"Long-term follow-up of patients with follicular lymphoma using next generation sequencing to detect minimal residual disease","volume":"24","author":"Chauhan","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10306","key":"2025112711214503600_bib23","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"2025112711214503600_bib24","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17","key":"2025112711214503600_bib25","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized Intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10466","key":"2025112711214503600_bib26","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"issue":"11","key":"2025112711214503600_bib27","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"issue":"13","key":"2025112711214503600_bib28","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/bloodadvances.2024012916","article-title":"Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis","volume":"8","author":"Reynolds","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2025112711214503600_bib29","first-page":"173","article-title":"Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes","volume":"110","author":"Serna","year":"2025","journal-title":"Haematologica"},{"issue":"9","key":"2025112711214503600_bib30","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s00277-023-05315-1","article-title":"COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphoma","volume":"102","author":"Nachar","year":"2023","journal-title":"Ann Hematol"},{"issue":"10","key":"2025112711214503600_bib31","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.immuni.2022.09.006","article-title":"SARS-CoV-2 in immunocompromised individuals","volume":"55","author":"DeWolf","year":"2022","journal-title":"Immunity"},{"issue":"8","key":"2025112711214503600_bib32","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"issue":"suppl 2","key":"2025112711214503600_bib33","article-title":"Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: results from a phase 3 study (inMIND) [abstract]","volume":"144","author":"Sehn","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025112711214503600_bib34","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood-2021-148778","article-title":"Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R\/R) follicular lymphoma (FL) [abstract]","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2025112711214503600_bib35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2021-145694","article-title":"Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed\/refractory follicular lymphoma: initial results from a phase Ib study [abstract]","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2025112711214503600_bib36","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"2025112711214503600_bib37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"2025112711214503600_bib38","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"key":"2025112711214503600_bib39","doi-asserted-by":"crossref","first-page":"102625","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"eBioMedicine"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/22\/2629\/2422151\/blood_bld-2025-029909-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/22\/2629\/2422151\/blood_bld-2025-029909-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:21:54Z","timestamp":1764260514000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/22\/2629\/547148\/Fixed-duration-epcoritamab-plus-R2-drives"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":39,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,11,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029909","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,27]]},"published":{"date-parts":[[2025,11,27]]}}}